MedTrace Logo

CX3CR1+T Cell Predict Immunotherapy Efficacy

NCT06054152 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2025-06-25

No results posted yet for this study

Summary

This study aimed to evaluate the correlation between the proportion of flow-sorted CX3CR1+T cells in peripheral blood and the CX3CR1+T-specific gene signature and the efficacy of immunotherapy.

Conditions

Interventions

DRUG

PD-1 inhibitor based immunotherapy

Patients received at least 4 cycles of PD-1 inhibitor-based immune monotherapy or chemoimmunotherapy. PD-1 drug selection should be limited in 4 types of PD-1 inhibitor approved by China FDA and launched in China and Opdivo or Keytruda.

Sponsors & Collaborators

  • Shanghai Pulmonary Hospital, Shanghai, China

    lead OTHER

Principal Investigators

  • Chang Chen, MD, Ph.D. · Shanghai Pulmonary Hospital, Shanghai, China

  • Deping Zhao, MD, Ph.D. · Shanghai Pulmonary Hospital, Shanghai, China

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-10
Primary Completion
2025-01-01
Completion
2025-06-20

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06054152 on ClinicalTrials.gov